- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05828511
Исследование «Окно возможностей», чтобы узнать, является ли линвосельтамаб безопасным и хорошо переносимым, а также насколько хорошо он работает у участников с недавно диагностированной множественной миеломой, которые еще не получали лечения. (LINKER-MM4)
Фаза 1/2 исследования линвосельтамаба (анти-BCMA X анти-CD3 биспецифического антитела) у ранее не леченных пациентов с симптоматической множественной миеломой
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible).
The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM.
This study consists of 2 phases:
- In Phase 1 Parts A and B, the study drug will be given to participants to study the side effects of the study drug and to establish the regimen (initial doses and full dose) of the study drug to be given to participants in Phase 2.
- In Phase 1 Part C, the study drug will be given to participants to study the side effects when using different initial doses of the study drug.
- In Phase 2, the study drug will be given to more participants to continue to assess the side effects of the study drug and to evaluate the activity of the study drug to shrink the tumor (multiple myeloma) in participants with NDMM.
The study is looking at several research questions, including:
- What side effects may happen from taking linvoseltamab?
- What the right dosing regimen is for linvoseltamab?
- How many participants treated with linvoseltamab have improvement of their disease and for how long?
- The effects of linvoseltamab study treatment before and after transplant
- How much linvoseltamab is in the blood at different times?
- Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects).
Обзор исследования
Статус
Условия
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
-
Barcelona, Испания, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Испания, 08908
- Institut Catala dOncologia (ICO Hospitalet)
-
Madrid, Испания, 28027
- Clinica Universidad de Navarra - Madrid
-
Madrid, Испания, 28006
- Universitary Hospital La Princesa
-
Salamanca, Испания, 37007
- Hospital Universitario de Salamanca
-
Valencia, Испания, 46026
- Hospital Universitari i Politecnic La Fe
-
-
Barcelona
-
Badalona, Barcelona, Испания, 08916
- Hospital Germans Trias i Pujol
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Испания, 28223
- Hospital Universitario Quiron Salud Madrid
-
-
Navarre
-
Pamplona, Navarre, Испания, 31008
- Clinica Universidad de Navarra
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Испания, 33011
- Hospital Universitario Central de Asturias
-
-
Valencia
-
Alicante, Valencia, Испания, 03010
- Hospital General Universitario Doctor Balmis Alicante
-
-
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90095
- University of California Los Angeles (UCLA)
-
Orange, California, Соединенные Штаты, 92868
- UC Irvine Health
-
-
Colorado
-
Denver, Colorado, Соединенные Штаты, 80218
- Colorado Blood Cancer Institute/SCRI
-
-
Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40207
- Norton Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Соединенные Штаты, 48201
- Karmanos Cancer Institute
-
-
New Jersey
-
New Brunswick, New Jersey, Соединенные Штаты, 08901
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Mineola, New York, Соединенные Штаты, 11501
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island
-
New York, New York, Соединенные Штаты, 10016
- Perlmutter Cancer Center
-
New York, New York, Соединенные Штаты, 10032
- Columbia University _ New York Presbyterian
-
Stony Brook, New York, Соединенные Штаты, 11794
- Stony Brook University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Соединенные Штаты, 28204
- Levine Cancer Institute
-
Durham, North Carolina, Соединенные Штаты, 27705
- Duke University Health System (DUHS)
-
-
Texas
-
Houston, Texas, Соединенные Штаты, 77030
- The University of Texas MD Anderson Cancer Center
-
-
-
-
-
Lille, Франция, 59000
- CHU De Lille
-
Montpellier, Франция, 342950
- Centre Hospitalier Universitaire (CHU) Montpellier
-
Paris, Франция, 75010
- Hopital Saint Louis
-
Paris, Франция, 75651
- University Hospitals Pitie Salpetriere - Charles Foix
-
-
Vienne
-
Poitiers, Vienne, Франция, 86021
- Centre Hospitalier Universitaire (CHU) de Poitiers
-
-
Île-de-France Region
-
Antony, Île-de-France Region, Франция, 92160
- Hopital Prive d'Antony
-
Paris, Île-de-France Region, Франция, 75015
- Hopital Necker
-
Villejuif, Île-de-France Region, Франция, 94800
- Gustave Roussy
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Confirmed diagnosis of symptomatic Multiple Myeloma (MM) by International Myeloma Working Group (IMWG) diagnosis criteria, as described in the protocol
- Response-evaluable myeloma, according to the 2016 IMWG response criteria, as defined in the protocol
- No prior therapy for MM, with the exception of prior emergent or palliative radiation and up to 1 month of single-agent corticosteroids, with washout periods as per the protocol
- Participants must have evidence of adequate bone marrow reserves and hepatic, renal and cardiac function as defined in the protocol
- Participants must be age <70 and have adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible. The specific thresholds for adequate organ function are as per institutional guidance.
Key Exclusion Criteria:
- Receiving any concurrent investigational agent with known or suspected activity against MM, or agents targeting the A proliferation-inducing ligand (APRIL)/ Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)/BCMA axis
- Known Central Nervous System (CNS) involvement with MM, known or suspected Progressive Multifocal Leukoencephalopathy (PML), a history of neurocognitive conditions, or CNS movement disorder, or history of seizure within 12 months prior to study enrollment
- Rapidly progressive symptomatic disease, (e.g. progressing renal failure or hypercalcemia not responsive to standard medical interventions), in urgent need of treatment with chemotherapy
- Diagnosis of non-secretory MM, active plasma cell leukemia primary light-chain (AL) amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or known POEMS syndrome (Plasma cell dyscrasia with polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Phase 1 cohorts
Linvoseltamab dose escalation (part A), dose expansion (part B), and evaluation of alternative step-up regimen (part C) for participants with NDMM who are treatment-naïve. |
Linvoseltamab will be administered by intravenous (IV) infusion
Другие имена:
|
|
Экспериментальный: Phase 2 - transplant ineligible cohort
Transplant-ineligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen until disease progression as per protocol. |
Linvoseltamab will be administered by intravenous (IV) infusion
Другие имена:
|
|
Экспериментальный: Phase 2 - transplant eligible cohort
Transplant-eligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen for a fixed duration of treatment as per protocol |
Linvoseltamab will be administered by intravenous (IV) infusion
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Incidence of Dose-Limiting Toxicities (DLTs)
Временное ограничение: End of the Observation period; up to day 28
|
Phase 1 |
End of the Observation period; up to day 28
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of TEAEs
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of Adverse Events of Special Interest (AESIs)
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of AESIs
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria
Временное ограничение: Up to 5 years
|
Phase 2 |
Up to 5 years
|
|
Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy
Временное ограничение: Up to 5 years
|
Phase 2 Transplant-eligible cohort |
Up to 5 years
|
|
Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy
Временное ограничение: Up to 5 years
|
Phase 2 Transplant-eligible cohort |
Up to 5 years
|
|
Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II
Временное ограничение: Up to 5 years
|
Phase 2 Transplant-ineligible cohort |
Up to 5 years
|
|
Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II
Временное ограничение: Up to 5 years
|
Phase 2 Transplant ineligible cohort |
Up to 5 years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Concentrations of Linvoseltamab in serum
Временное ограничение: Post-Last Linvoseltamab Dose, up to 12 weeks
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 12 weeks
|
|
Concentrations of total soluble B-Cell Maturation Antigen (BCMA)
Временное ограничение: Post-Last Linvoseltamab Dose, up to 12 weeks
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 12 weeks
|
|
Incidence of Anti-Drug Antibodies (ADAs) to Linvoseltamab
Временное ограничение: Post-Last Linvoseltamab Dose, up to 30 days
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 30 days
|
|
Magnitude of ADAs to Linvoseltamab
Временное ограничение: Post-Last Linvoseltamab Dose, up to 30 days
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 30 days
|
|
Objective Response Rate (ORR) measured using the IMWG criteria
Временное ограничение: Up to 5 years
|
Phase 1 |
Up to 5 years
|
|
Duration Of Response (DOR) measured using the IMWG criteria
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Progression-Free Survival (PFS) measured using the IMWG criteria
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Proportion of participants achieving MRD-negative status (at 10^-5) in participants with NDMM measured using the IMWG criteria
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of TEAEs
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of TEAEs
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of AESIs
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of AESIs
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
ORR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Временное ограничение: Up to 5 years
|
Phase 2 |
Up to 5 years
|
|
MRD-negative status of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
DOR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
PFS of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Overall Survival (OS) of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Time To Response (TTR) as measured using the IMWG criteria
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
ORR by risk levels
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
MRD-negative status by risk levels
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
DOR by risk levels
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
TTR by risk levels
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
PFS by risk levels
Временное ограничение: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of MRD-negative status
Временное ограничение: Up to 5 years
|
Phase 2 |
Up to 5 years
|
|
Cluster of Differentiation 34+ (CD34+) stem cell yield
Временное ограничение: At cycle 4 of induction (each cycle is 28 days long)
|
Phase 2 Transplant-eligible cohort |
At cycle 4 of induction (each cycle is 28 days long)
|
|
Time to neutrophil engraftment
Временное ограничение: Up to 100 days post-transplant
|
Phase 2 Transplant-eligible cohort |
Up to 100 days post-transplant
|
|
Time to platelet engraftment
Временное ограничение: Up to 100 days post-transplant
|
Phase 2 Transplant-eligible cohort |
Up to 100 days post-transplant
|
|
PFS after ASCT followed by 3 cycles of linvoseltamab
Временное ограничение: Up to 5 years
|
Phase 2 Transplant-eligible cohort |
Up to 5 years
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Clinical Trial Management, Regeneron Pharmaceuticals
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Сосудистые заболевания
- Сердечно-сосудистые заболевания
- Новообразования
- Заболевания иммунной системы
- Новообразования по гистологическому типу
- Гематологические заболевания
- Лимфопролиферативные заболевания
- Иммунопролиферативные заболевания
- Новообразования, Плазматические клетки
- Нарушения гемостаза
- Парапротеинемии
- Нарушения белков крови
- Геморрагические расстройства
- Гемики и лимфатические заболевания
- Множественная миелома
Другие идентификационные номера исследования
- R5458-ONC-2158
- 2022-500800-24-00 (Ктис)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Сроки обмена IPD
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
Критерии совместного доступа к IPD
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- МКФ
- АНАЛИТИЧЕСКИЙ_КОД
- КСО
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .